Directorate Change

RNS Number : 0995U

Dechra Pharmaceuticals PLC

31 March 2021

 

31 March 2021

Dechra^® Pharmaceuticals PLC

(Dechra, the Company or the Group)

Appointment of Denise Goode as Non-Executive Director of Dechra Pharmaceuticals PLC

Dechra is pleased to announce that, with effect from 26 April 2021, Denise Goode will take up a new position as a Non-Executive Director of the Company.  Denise will be a member of the Group's Audit, Remuneration and Nomination Committees with the intention that she will be appointed as Chairman of the Audit Committee upon Julian Heslop's retirement as Audit Committee Chairman following the 2021 Annual General Meeting.

Denise brings a wealth of financial, commercial and life science industry experience, both from her extensive career as a senior executive and from board roles held since 2008.  She has a deep understanding of the pharmaceuticals sector and is highly experienced in business development.

Denise is currently a Non-Executive Director of Abliva AB, a NASDAQ Sweden listed company, where she is Chair of the Remuneration Committee and a member of the Audit Committee.  She is also Vice President, Business Development at AnaMar AB, a Swedish based private company.  In 2014 Denise established QED Life Sciences Limited, through which as CEO she advises and supports the strategic direction of biotech companies.  Prior to this, Denise was Chair of the Audit Committee at Oxford Bioscience Network from 2014 to 2017 and of AstraZeneca Ireland Operations Ltd  from 2008 to 2013.  Over her 20 year global career with AstraZeneca Pharmaceuticals PLC, Denise held senior leadership roles within the finance and commercial activities of the global entity. She is a Fellow of the Institute of Chartered Accountants in England and Wales.

Commenting on the appointment Tony Rice, Chairman, Dechra Pharmaceuticals said:

" On behalf of the Board and all stakeholders I am delighted to welcome Denise to Dechra.  She will add significant pharmaceutical and financial experience and capabilities to the team as well as providing continuity during the next phase of Dechra's growth and development."

There are no other disclosures to be made in respect of Denise Goode, pursuant to Listing Rule 9.6.13R.

Enquiries to:

Dechra Pharmaceuticals PLC

Ian Page, Chief Executive Officer

Office:  [phone]

e-mail: [e-mail]

TooleyStreet Communications Ltd

Fiona Tooley, Director Mobile: [phone] e-mail: [e-mail]

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. 

For more information please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

BOAFIFFDVEILVIL